Research Analysts Issue Forecasts for SXTP Q1 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for 60 Degrees Pharmaceuticals in a research note issued on Tuesday, March 31st. HC Wainwright analyst M. Keller forecasts that the company will earn ($0.53) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.21) EPS, FY2027 earnings at ($0.54) EPS and FY2028 earnings at ($0.44) EPS.

A number of other equities research analysts have also weighed in on the company. Wall Street Zen upgraded 60 Degrees Pharmaceuticals to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.60.

60 Degrees Pharmaceuticals Price Performance

60 Degrees Pharmaceuticals stock opened at $1.86 on Friday. The business has a fifty day moving average price of $2.92 and a 200-day moving average price of $3.84. 60 Degrees Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $17.68. The stock has a market capitalization of $1.97 million, a price-to-earnings ratio of -0.13 and a beta of 3.27.

Key 60 Degrees Pharmaceuticals News

Here are the key news stories impacting 60 Degrees Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts sharply (FY2026 from ($5.92) to ($2.21); FY2027 to ($0.54); FY2028 to ($0.44)) while keeping a “Buy” rating and a $24.00 price target — the upgrade in estimates and high price target support a potential re‑rating if clinical or operational progress continues. HC Wainwright Research Note
• Positive Sentiment: Zacks upgraded SXTP to a Zacks Rank #2 (Buy), signaling growing optimism among independent research providers and adding to buying interest from model‑based and retail investors. 60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy
• Neutral Sentiment: 60 Degrees will gain media exposure with interviews airing on the RedChip “Small Stocks, Big Money” show on Bloomberg TV — this can increase awareness and short‑term volume but does not itself change fundamentals. Bloomberg TV Interview Announcement
• Negative Sentiment: Material risks remain: SXTP is loss‑making (consensus negative EPS), has a very small market cap and low average trading volume — these factors make the stock volatile and can limit sustained upside even after bullish research notes.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.